AnaptysBio Inc.
ANAB | NASDAQ
$55.11
-$0.09 (-0.16%)
Sep 21, 2026, 12:49 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 234.6M | 91.28M | 17.16M | 10.29M | 63.18M | 75M |
Cost of Revenue | 2.42M | 163.84M | 132.28M | 88.8M | 98.5M | 80.03M |
Gross Profit | 232.18M | -72.56M | -115.13M | -78.51M | -35.32M | -5.03M |
Operating Income | 47.9M | -114.95M | -164.41M | -115.15M | -56.81M | -23.88M |
Interest Income | 13.5M | 19.79M | 18.87M | 7.55M | 431K | 3.96M |
Pretax Income | -13.07M | -145.23M | -163.62M | -128.7M | -57.8M | -19.93M |
Net Income | -13.23M | -145.23M | -163.62M | -128.72M | -57.8M | -19.93M |
Selling & General & Admin | 50.74M | 42.39M | 41.95M | 36.64M | 21.49M | 18.85M |
Research & Development | 135.97M | 163.84M | 139.62M | 88.8M | 98.5M | 80.03M |
Other Expenses | -2.42M | -163.84M | -132.28M | -88.8M | -98.5M | -80.03M |
Operating Expenses | 184.28M | 42.39M | 49.29M | 36.64M | 21.49M | 18.85M |
Interest Expense | 79.89M | 50.09M | 18.08M | 21.11M | 1.45M | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 186.71M | 206.23M | 181.57M | 125.44M | 119.99M | 98.88M |
Income Tax Expense | 164K | 3K | -4K | 24K | n/a | n/a |
Shares Outstanding (Basic) | 27.79M | 28.38M | 26.92M | 28.17M | 27.43M | 27.3M |
Shares Outstanding (Diluted) | 31.34M | 28.38M | 26.92M | 28.17M | 27.43M | 27.3M |
EPS (Basic) | -0.46 | -5.12 | -6.08 | -4.57 | -2.11 | -0.73 |
EPS (Diluted) | -0.46 | -5.12 | -6.08 | -4.57 | -2.11 | -0.73 |
EBITDA | 50.32M | -92.74M | -156.42M | -105.26M | -55.71M | -19.37M |
EBIT | 47.9M | -95.14M | -157.07M | -107.59M | -57.8M | -19.93M |
Depreciation & Amortization | 2.42M | 2.4M | 652K | 2.34M | 2.09M | 559K |
Add to Watchlist
Select watchlists to add or remove ANAB